Composition
- Active ingredients
- NINTEDANIB EQ 150MG BASE
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- NINTEDANIB 100MG · CapsuleANDA218472-002 · Tentative approval
- NINTEDANIB 25MG · CapsuleANDA218472-003 · Tentative approval
- NINTEDANIB 100MG · CapsuleANDA219708-002 · Tentative approval
- NINTEDANIB 100MG · CapsuleANDA219371-002 · Tentative approval
- NINTEDANIB 25MG · CapsuleANDA219371-003 · Tentative approval
- NINTEDANIB EQ 150MG BASE · CapsuleANDA212732-002 · Tentative approval
- NINTEDANIB EQ 100MG BASE · CapsuleANDA212732-001 · Tentative approval
- NINTEDANIB EQ 150MG BASE · CapsuleThis page
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application ANDA215123.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Brand name
- Nintedanib
- Route
- Oral
- Dosage form
- Capsule
- Applicant
- Eugia Pharma Speclts
- Status
- Tentative approval
- FDA approval
- 4 Feb 2026
- Application
- ANDA215123-002